Reuters
The FDA (news - web sites) said the study it commissioned from the Institute of Medicine (news - web sites) (IOM) is one of many new measures in response to criticism of the agency's handling of Vioxx, as well as the risks of antidepressants used by children.
"We need to have a look at what we're doing. We think we're doing it right, but there's been criticism because of Vioxx and (antidepressants)," Acting FDA Commissioner Lester Crawford told Reuters in an interview.
More...
|